Skip to content
10-Q

Quarterly Report

ANTIVIRAL TECHNOLOGIES, INC.

0001137050-14-000264

← back to feed
Filed
Nov 13, 2014 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2014 · Sep 30, 2014 150M sh
Operating Cash Flow Q3 2014 · Sep 30, 2014 −$39.1K
Operating Cash Flow Q3 2014 · Sep 30, 2014 −$1.33M
Operating Cash Flow Q3 2014 · Sep 30, 2013 −$36.25K
Cash And Equivalents Q3 2014 · Sep 30, 2014 $4.04K
Cash And Equivalents Q3 2014 · Dec 31, 2013 $499
Cash And Equivalents Q3 2014 · Sep 30, 2013 $641
Cash And Equivalents Q3 2014 · Dec 31, 2012 $699
Stockholders Equity Q3 2014 · Sep 30, 2014 −$2.95M
Stockholders Equity Q3 2014 · Dec 31, 2013 −$2.68M
Current Liabilities Q3 2014 · Sep 30, 2014 $1.79M
Current Liabilities Q3 2014 · Dec 31, 2013 $1.74M
Total Liabilities Q3 2014 · Sep 30, 2014 $3.43M
Total Liabilities Q3 2014 · Dec 31, 2013 $3.17M
Current Assets Q3 2014 · Sep 30, 2014 $4.04K
Current Assets Q3 2014 · Dec 31, 2013 $501
Total Assets Q3 2014 · Sep 30, 2014 $473.17K
Total Assets Q3 2014 · Dec 31, 2013 $484.16K
Sga Expense Q3 2014 · Sep 30, 2014 $90.91K
Sga Expense Q3 2014 · Sep 30, 2014 $274.85K
Sga Expense Q3 2014 · Sep 30, 2014 $2.78M
Sga Expense Q3 2014 · Sep 30, 2013 $76.91K
Sga Expense Q3 2014 · Sep 30, 2013 $259.74K
Net Income Q3 2014 · Sep 30, 2014 −$90.91K
Net Income Q3 2014 · Sep 30, 2014 −$274.85K
Net Income Q3 2014 · Sep 30, 2014 −$2.95M
Net Income Q3 2014 · Sep 30, 2013 −$77.53K
Net Income Q3 2014 · Sep 30, 2013 −$260.44K